Effects of liver disease on the pharmacokinetics of intravenous and oral chlordesmethyldiazepam

  title={Effects of liver disease on the pharmacokinetics of intravenous and oral chlordesmethyldiazepam},
  author={Silvio R. Bareggi and Rodolfo Pirola and P Potvin and Ghislain Devis},
  journal={European Journal of Clinical Pharmacology},
We studied the pharmacokinetics of a single 0.5-mg i.v. dose of chlordesmethyldiazepam in 8 patients with liver disease and in 12 age-matched healthy controls. The kinetics were also studied of a single 1-mg oral dose in the patients with liver disease. After i.v. administration the kinetics of total chlordesmethyldiazepam in patients with liver disease differed from those in controls: elimination half-life was almost twice that in controls (395 and 204 h), as a consequence of a marked… 

Quantification of chlordesmethyldiazepam by liquid chromatography-tandem mass spectrometry: application to a cloxazolam bioequivalence study.

A rapid, sensitive and specific LC-MS/MS method was developed and validated for quantifying chlordesmethyldiazepam (CDDZ or delorazepam), the active metabolite of cloxazolam, in human plasma and indicated bioequivalence since all ratios were as proposed by FDA and ANVISA.

Understanding the pharmacokinetics of anxiolytic drugs

A need for a more balanced assessment of the benefits and risks associated with benzodiazepine use, particularly considering pharmacokinetic profile of the drugs to ensure that patients, who would truly benefit from these agents, are not denied appropriate treatment.

Designer benzodiazepines versus prescription benzodiazepines: can structural relation predict the next step?

This review would highlight the distinct characteristics of some of the most commonly abused designer benzodiazepine analogies in relation to their original prescription BZD compounds.

Prediction of human systemic, biologically relevant pharmacokinetic (PK) properties using quantitative structure pharmacokinetic relationships (QSPKR) and interspecies pharmacokinetic allometric scaling (PK-AS) approaches for four different pharmacological classes of compounds

This research developed and validated QSPKR models for predicting in-vivo human, systemic biologically relevant PK properties of four, preselected, pharmacological classes of drugs, as well as PK allometric scaling (PK-AS) models for BZD and NMB, using pertinent human and animal systemic PK information from published literature.



Pharmacokinetics of Midazolam Following Intravenous and Oral Administration in Patients with Chronic Liver Disease and in Healthy Subjects

On a pharmacokinetic basis a reduced dosage of midazolam to patients with advanced cirrhosis of the liver is recommended, and on a hypnotic basis the hypnotic effects of midAZolam were similar in both groups.

Pharmacokinetics of intravenous and oral chlordesmethyldiazepam in patients on regular haemodialysis

SummaryThe pharmacokinetics of a single 2 mg IV dose of chlordesmethyldiazepam has been studied in 11 patients with renal failure on regular haemodialysis and in 11 age-matched healthy controls. The

Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease.

At least two steps in diazepam metabolism are impaired in patients with liver disease, and the accumulation of DD after multiple dosage could be explained by the fact that it is formed faster from D than it is eliminated.

Pharmacokinetics of oral brotizolam in patients with liver cirrhosis.

In two patients hardly any drug elimination was observed, indicating severe impairment of drug metabolizing activity, and the prolongation of the elimination half-life was likely to be due to a decrease in clearance and increase in volume of distribution.

The effects of age and chronic liver disease on the elimination of temazepam

This study adds further support to the observation that drugs which undergo ether glucuronidation have normal elimination patterns in patients with liver disease and Temazepam may prove to be a useful hypnotic sedative in patientsWith liver disease.

Effects of aging and liver disease on disposition of lorazepam

It is concluded that the degree of impairment, if any, in the metabolism of lorazepam in patients with liver disease is considerably less than that of certain other drugs including related benzodiazepines.

Pharmacokinetics and bioavailability of intravenous and oral chlordesmethyldiazepam in humans

SummarySix healthy, fasting volunteers were given single doses of chlordesmethyldiazepam by 1 mg i. v., or as drops or tablets. Chlordesmethyldiazepam and its metabolite, lorazepam, in multiple

Clinical pharmacokinetics of chlordiazepoxide in patients with alcoholic hepatitis

The clearance of chlordiazepoxide from the systemic circulation was studied in 20 subjects which included 15 patients with alcoholic hepatitis and 5 normal volunteers, and a significant correlation between clearance and the variables age, albumin, and lactate dehydrogenase suggested that over a short period of time changes in albumin and lactates could be potentially useful in predicting clearance changes in a single individual.

Normal disposition of oxazepam in acute viral hepatitis and cirrhosis.

Unlike many other sedatives, oxazepam is eliminated normally in patients with parenchymal liver disease an therefore, on pharmacokinetic grounds, seems to be an excellent sedative for use in such persons.